Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Head-to-Head Comparison of Botulinum Neurotoxin Type A Products for Glabellar Rhytides
2024-516865-35-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of botulinum toxin type A and relugolix + estradiol + norethindrone in glabellar furrowing (5 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Time until loss of treatment effect at week 16. Planned start Mar 2025; status: authorised.
02
Drugs
botulinum toxin type Arelugolix + estradiol + norethindrone
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2024-516865-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516865-35-01.